<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113668</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-101</org_study_id>
    <nct_id>NCT04113668</nct_id>
  </id_info>
  <brief_title>The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants</brief_title>
  <official_title>AN OPEN-LABEL, SINGLE-SEQUENCE, CROSSOVER STUDY TO INVESTIGATE THE EFFECTS OF UGT1A9 INHIBITOR DIFLUNISAL, AT STEADY-STATE, ON PHARMACOKINETICS OF A SINGLE DOSE OF BMS-986165 IN HEALTHY MALE AND FEMALE VOLUNTEERS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BMS-986165 Is broken down by the body through multiple pathways. This study Investigates the
      effect of blocking one pathway in the drug levels of BMS-986165 in health subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Actual">November 25, 2019</completion_date>
  <primary_completion_date type="Actual">November 19, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-986165 with and without UGT1A9 inhibitor</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time AUC (0-T) of BMS-986165 with and without UGT1A9 inhibitor</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time AUC(INF) for BMS-986165 with and without UGT1A9 inhibitor</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>up to 48 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with 12-lead Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>up to 48 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Examination of weight</measure>
    <time_frame>up to 48 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of changes in blood pressure</measure>
    <time_frame>up to 20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of changes in body temperature</measure>
    <time_frame>up to 20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of changes in respiratory rate</measure>
    <time_frame>up to 20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinical significant changes in lab assessment of blood serum</measure>
    <time_frame>up to 48 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Clinically significant changes in assessment of blood</measure>
    <time_frame>up to 20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Clinically significant changes in lab assessment of urine</measure>
    <time_frame>up to 20 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Arm A: Single Dose (BMS-986165)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B:Diflunisal and Single Dose (BMS-986165)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Arm A: Single Dose (BMS-986165)</arm_group_label>
    <arm_group_label>Arm B:Diflunisal and Single Dose (BMS-986165)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diflunisal</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Arm B:Diflunisal and Single Dose (BMS-986165)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Women and men must agree to follow instructions for methods of contraception.

          -  Participants must be willing and able to complete all study-specific procedures and
             visits.

          -  A healthy participant, as determined by no clinically significant deviation from
             normal in medical history, physical examination, ECGs, and clinical laboratory
             determinations.

          -  WOCBP must have a negative serum or urine pregnancy test within 24 hours prior to the
             start of study treatment.

        Exclusion Criteria:

          -  Any significant acute or chronic medical condition that presents a potential risk to
             the participant and/or may compromise the objectives of the study, including a history
             of active liver disease

          -  History of biliary disorders, including Gilbert's syndrome or Dubin- Johnson disease,
             in addition to, current or recent gastrointestinal disease that could impact the
             absorption of study drug.

          -  Participants using electronic cigarettes or nicotine-containing products who have
             stopped smoking less than 6 months prior to dosing on Day 1.

          -  Consumption of chargrilled meat, quinine, or any nutrient known to modulate CYP enzyme
             activity within 14 days prior to first administration of study treatment.

          -  History of any significant drug allergy

        Other inclusion/exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences - Lenexa</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diflunisal</mesh_term>
    <mesh_term>BMS-986165</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

